 Connection
Kurt Stenmark to Lung Diseases
This is a "connection" page, showing publications Kurt Stenmark has written about Lung Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.383 |
|
|
|
-
Gu S, Goel K, Forbes LM, Kheyfets VO, Yu YA, Tuder RM, Stenmark KR. Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension. Compr Physiol. 2023 01 30; 13(1):4295-4319.
Score: 0.471
-
D'Alessandro A, Nozik-Grayck E, Stenmark KR. Identification of Infants at Risk for Chronic Lung Disease at Birth. Potential for a Personalized Approach to Disease Prevention. Am J Respir Crit Care Med. 2017 10 15; 196(8):951-952.
Score: 0.326
-
Prakash YS, Tschumperlin DJ, Stenmark KR. Coming to terms with tissue engineering and regenerative medicine in the lung. Am J Physiol Lung Cell Mol Physiol. 2015 Oct 01; 309(7):L625-38.
Score: 0.280
-
Bailey KE, Floren ML, D'Ovidio TJ, Lammers SR, Stenmark KR, Magin CM. Tissue-informed engineering strategies for modeling human pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 2019 02 01; 316(2):L303-L320.
Score: 0.088
-
Buehler PW, Baek JH, Lisk C, Connor I, Sullivan T, Kominsky D, Majka S, Stenmark KR, Nozik-Grayck E, Bonaventura J, Irwin DC. Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism. Am J Physiol Lung Cell Mol Physiol. 2012 Aug 15; 303(4):L312-26.
Score: 0.056
-
Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, Asosingh K, Balaban R, Bauer N, Bhattacharya J, Bogaard H, Choudhary G, Dorn GW, Dweik R, Fagan K, Fallon M, Finkel T, Geraci M, Gladwin MT, Hassoun PM, Humbert M, Kaminski N, Kawut SM, Loscalzo J, McDonald D, McMurtry IF, Newman J, Nicolls M, Rabinovitch M, Shizuru J, Oka M, Polgar P, Rodman D, Schumacker P, Stenmark K, Tuder R, Voelkel N, Sullivan E, Weinshilboum R, Yoder MC, Zhao Y, Gail D, Moore TM. Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med. 2010 Dec 15; 182(12):1554-62.
Score: 0.050
-
Takeda K, Okamoto M, de Langhe S, Dill E, Armstrong M, Reisdorf N, Irwin D, Koster M, Wilder J, Stenmark KR, West J, Klemm D, Gelfand EW, Nozik-Grayck E, Majka SM. Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease. Anat Rec (Hoboken). 2009 Jul; 292(7):1045-61.
Score: 0.046
-
Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M. Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda). 2006 Apr; 21:134-45.
Score: 0.037
-
Irwin DC, Baek JH, Hassell K, Nuss R, Eigenberger P, Lisk C, Loomis Z, Maltzahn J, Stenmark KR, Nozik-Grayck E, Buehler PW. Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration. Free Radic Biol Med. 2015 May; 82:50-62.
Score: 0.017
-
Fasules JW, Stenmark KR, Henson PM, Voelkel NF, Reeves JT. Neither anticoagulant nor nonanticoagulant heparin affects monocrotaline lung injury. J Appl Physiol (1985). 1987 Feb; 62(2):816-20.
Score: 0.010
-
Wescott JY, Balazy M, Stenmark KR, Murphy RC. Analysis of leukotriene D4 in human lung lavage by HPLC, RIA and mass spectrometry. Adv Prostaglandin Thromboxane Leukot Res. 1986; 16:353-61.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|